Several polycyclic aromatic hydrocarbons and nitrated polycyclic aromatic hydrocarbons (PAHs/NPAHs) such as benzo [a]pyrene and 1-nitropyrene are mutagens and/or carcinogens. These compounds secondarily generate PAH hydroxides, ketones, and quinones through atmospheric and metabolic reactions. The health effects of these compounds is now an important social concern. For example, lung cancer, bronchitis, whistling and so on. In this work, we evaluated toxicities of 25 PAH derivatives (hydroxides, ketones and quinones) in terms of aryl hydrocarbon receptor (AhR) binding and thyroid hormone-related endpoints using three in vitro bioassays: dioxinresponsive chemical-activated luciferase gene expression (DR-CALUX), thyroid receptor β chemical-activated luciferase gene expression (TRβ-CALUX), and competitive human transthyretin-binding (TTR-binding) assays. Eleven of the 25 PAH derivatives had AhR agonist activity, six had AhR antagonist activity and seven had TRpotentiation activity in the TR-CALUX. Furthermore, PAH quinones and hydroxides had strong TTR-binding activity. 3,4-Dihydrobenz[a]anthracen-1(2 H)-one had the strongest agonist activity (EC 20 : 0.4 µM) as determined by DR-CALUX. PAH ketones showed stronger activity than the control and significant difference by statistical analysis. Benzo[c]phenanthrene-[1,4]-quinone was the most TTR-active compound (IC 50 : 2.5 µM). Both PAH ketones and quinones, which have functional groups with low polarity, had significant activities in all tested assays. These in vitro results suggest that PAH derivatives might have various toxic activities in animals. For estimating the health effects and accessing the environmental risks of PAHs, further studies on the toxicity mechanisms are necessary.
INTRDUCTION
Polycyclic aromatic hydrocarbons (PAHs), which originate from combustion of biomass or fossil fuels such as petroleum and coal, are pollutants that are distributed ubiquitously throughout the environment. Many of them induce mutagenic and/or carcinogenic effects. 1) Furthermore, PAHs are known to possess aryl hydrocarbon receptor (AhR) binding activity, which has been used as a criterion for dioxin-like activity. 2) In fact, AhR-derived gene expressions by novel AhR agonists such as * To whom correspondence should be addressed: Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan. Tel.: +81-76-234-4458; Fax: +81-76-234-4456; E-mail: k.bekki@ stu.kanazawa-u.ac.jp polychlorinated dibenzo-p-dioxins/dibenzofurans (PCDD/DFs) and polychlorinated biphenyls (PCBs) are associated with various diseases: weight loss, thymus shrinking, hepatic toxicity, teratogenesis, reproduction disorders, endocrine disorders and cancer. 3, 4) PAHs are more easily metabolized than halogenated compounds, but they also elicit several toxic and biochemical responses such as derivation of drug-metabolizing enzymes (cytochrome P450 1A1, 1A2, 1B1, etc.). Additionally, PAHs are transformed into derivatives by chemical reactions in the air and metabolic reactions in the body. For example, oxygenated PAHs such as ketones and quinones are formed by either combustion or gas phase photooxidation (in airborne particles). 5) The concentration of 9,10-phenanthrenquinone (9,10-PQ) was measured in the range from 0.138 to 0.690 ng m −3 at Nagasaki, Japan. 6) The levels of 9,10-PQ were correlated with those of phenanthrene, a parent compound of 9,10-PQ, up to a few ng m −3 . Furthermore, PAH quinones are generated by metabolizing PAHs in the presence of P450, epoxide hydrolase and some other metabolic enzymes. 7) Some recent reports described the toxicity of PAH derivatives. Among toxic PAH derivatives, PAH hydroxides are androgen antagonists 8) and PAH quinones induce the generation of reactive oxygen species (ROS). 9) Furthermore, polyhalogenated aromatic hydrocarbons (PHAHs), their hydroxylated derivatives 10) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) bind to thyroid hormone transporting protein, transthyretin (TTR) 11) and reduce the T4 level in rat blood plasma. 12) But the effects of PAH and PAH derivatives on the mechanisms is unknown, in spite of their high concentrations in the atmosphere suggesting large amount of human exposure.
The goal of this study was to determine the toxic potentials of 25 PAH derivatives including hydroxides, ketones, and quinones in terms of AhR binding and thyroid hormone-related endpoints using three in vitro bioassays: dioxin-responsive chemical-activated luciferase gene expression (DR-CALUX) , thyroid receptor β chemical-activated luciferase gene expression (TRβ-CALUX) and competitive human TTR-binding assays.
MATERIALS AND METHODS
Materials --We selected following twenty-five PAH derivatives (eight ketones, nine quinines and eight hydroxides) having two to four rings in terms of their existing in the air, 13) endocrine disruption and strong ROS producing activity. Anthrone, benzanthrone, 9-fluorenone, 2-hydroxy-9-fluorenone, 2,2 -biphenol, 1,2-naphthoquinone (1,2-NQ), 1,2-dihydroxynaphthalene, and 4,4 -biphenol were purchased from Tokyo Chemical Industry Co. Ltd. , and 9-hydroxyphenanthrene (9-OHPhe) were purchased from Chiron AS (Trondheim, Norway). 1,2-Benzanthraquinone (1,2-BAQ) was purchased from Wako Pure Chemical Industries Ltd. (Tokyo, Japan). The respective structures of the PAH derivatives listed above are presented in Fig. 1 . Each concentration of the test compound was prepared in dimethylsulfoxide (DMSO). DR-CALUX Assay --AhR binding activity was measured using the DR-CALUX assay using the rat hepatoma H4IIE cell line with an AhR-regulated luciferase gene construct (H4IIE-luc). The H4IIE-luc cell line was obtained from BioDetection Systems B.V. (Amsterdam, The Netherlands). The cells were cultured in alpha-minimal essential medium (α-MEM) (Invitrogen Corp., New York, NY, U.S.A.) supplemented with 10% fetal bovine serum (FBS) at 37 • C under 5% CO 2 . The cells were seeded into a 96-well microplate and the cells with 90-95% confluence were used for exposure. All test compounds were evaluated in terms of agonist, antagonist, and potentiating activities. For evaluation of agonistic activity, the cells were exposed to 2,3,7,8-TCDD standard series (0, 0.1, 0.3, 1, 3, 10, 30, 100, 300 pM in well) and experimental samples in the culture medium containing 0.4% DMSO in the same microplate. After 24 hr of exposure, the medium was removed. Then the microplate was filled with 50 µl of Meliorastar-LT (Toyo B-net Co. Ltd., Tokyo, Japan). After 10 min of enzyme reaction in a dark place at room temperature, luciferase activity was measured using a luminometer (AB-2100; ATTO Bioscience, Tokyo, Japan) for 10 s per well. For data analysis, after correcting for background activity (DMSO control), luciferase activities by 2,3,7,8-TCDD were fitted using software for a user-defined curve fit (Slide Write Plus ver. 6.00; Advanced Graphics Software, St. California, Encinitas, U.S.A.). The curve was y = a 0 /[1+(x/a 1 ) a 2 ] with the following parameters: y = measured luciferase activity; x = concentration; a 0 = maximum luciferase activity; a 1 = EC 50 ; and a 2 = curve slope. For evaluation of agonistic activity, full dose-response curves were not obtainable for the tested compounds. Consequently, luciferase activities of the tested compounds corresponding to EC 5 , EC 20 , and EC 50 (5, 20 , and 50% Effective Concentrations) of 2,3,7,8-TCDD were used to define EC 5 , EC 20 , and EC 50 concentrations of each compound, as described in a previous report. 14) On the other hand, for measurement of antagonist and potentiation activities, the cells were exposed to 2,3,7,8-TCDD standard (EC 50 : 7.5 pM in well) and experimental samples together. The luciferase activity was measured using a luminometer after 24 hr of exposure. Antagonistic and potentiation effects were defined by the capacity of a tested compound to inhibit or enhance the luciferase activity induced by 2,3,7,8-TCDD. Here, potentiation means an increase of agonistic activity through co-exposure of 2,3,7,8-TCDD and a non-agonistic compound. TR-CALUX Assay --Human TRβ-binding activity was measured using the TR-CALUX assay with the human osteosarcoma U2OS cell line and a human thyroid receptor β regulated luciferase gene construct (U2OS-luc) The U2OS-luc cell line was obtained from BioDetection Systems B.V. (Amsterdam, The Netherlands). The cells were cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% FBS treated by activated carbon, sterilized MEM non-essential amino acids, (100×) Solution (NEAA) (Invitrogen Corp., New York, NY, U.S.A.), NaHCO 3 (Kanto Chemical Co. Inc., Tokyo, Japan), penicillin/streptomycin (Sigma-Aldrich Corp.), and G-418 disulfate (Sigma-Aldrich Corp.) at 37 • C under 7.5% CO 2 . The cells were seeded into 96-well microplates and the cells with 90-95% confluence were used for exposure. The cells were exposed to 200 µl/well T3 standard series (0, 0.04, 0.12, 0.4, 1.2, 4, 12, 40, 120, and 400 nM in well) or experimental samples in the culture medium containing 0.1% DMSO. After 48 hr of exposure, the medium was removed and the microplate was filled with 50 µl of Meliorastar-LT (Toyo B-net Co. Ltd.). After eight-minute enzyme reaction on the plate shaker, the luciferase activity was measured in a multilabel counter (PerkinElmer Inc., Tokyo, Japan). For measurement of the antagonist and potentiation activities, the cells were exposed to T3 standard (EC 50 : 2nM in well) and experimental reagents together for 48 hr, and luciferase activity was measured using the multilabel counter. Data analyses for evaluation of agonistic/antagonistic/potentiation activities were conducted similarly to those for DR-CALUX. TTR-Binding Assay --Human TTR (SigmaAldrich Corp.; 30 nm) was incubated overnight at 4 • C in a final volume of 200 µl 0.1 M Tris-HCl buffer (pH 8.0; 0.1 M NaCl, 0.1 mM ethylene diamine tetra-acetic acid (EDTA)) with a mixture of 125 I-labeled (PerkinElmer Inc.; 3.7 MBq) and 125 Iunlabeled T4 (Sigma-Aldrich Corp.; 110 nM), with test compounds (maximum concentration 25 µM) or cold T4 (reference material) as competitors. All treatments and carrier controls contained 2.5% DMSO. When the binding equilibrium was reached, TTR-bound and free 125 I-T4 were separated on 1-ml Biogel P-6 pg columns and spin-force eluted with 200 µl Tris-HCl buffer (1 min, 1000 rpm, 4 • C). The TTR-bound 125 I-T4-containing eluate was counted for radioactivity using a gamma counter (WIZARD 1480; PerkinElmer Inc.). Competition-bindings of T4 standards and standard substances were expressed as relative 125 I-T4 TTR-binding (% of DMSO control) against competitors. A calibration competition-binding curve for T4 standards (0, 4, 8, 16, 32, 64, 128, 256, 512, 1024 nM in tube) were also fitted using a user-defined curve fit (Slide Write Plus ver. 6.00; Advanced Graphics Software) of y = a 0 /[1+(x/a 1 ) a 2 ], for which y = measured 125 I-T4 TTR-binding, x = concentration, a 0 = 125 I-T4 TTR-binding of DMSO control, a 1 = IC 50 , and a 2 = curve slope. All measurements were conducted in duplicate. All experiments were performed twice. Cytotoxicity --Cytotoxicity was measured for the DR-CALUX and TR-CALUX cells to ensure that reduction activity resulted from antagonistic responses and not by cytotoxicity. The reference agonist (100 × EC 50 ) was exposed to each assay cells with a sample which showed antagonistic activity. A similarly referenced agonist (EC 50 ) and the same sample were also exposed to each assay cell. Antagonistic responses in cell-based bioassays were competed out in most cases by excess of the reference agonist (100 × EC 50 ), so inhibition might be attributable to true antagonism and not to cytotoxicity. Statistics --The statistical significance of the activity difference between compound and control groups was determined using a Student's t-test (p < 0.05). The agonist, antagonist or potentiation activity was evaluated when the significant difference was observed at least one of the highest exposure concentration.
RESULTS

DR-CALUX Assay
Eleven PAH derivatives showed marked AhR agonist activity (Fig. 2) . Five PAH derivatives showed AhR antagonist activity (Fig. 3) . Table 1 shows results of EC 5 and EC 20 of the AhR agonist compounds. Although EC 5 and EC 20 do not show the same ranking order, the tendency is the same. The most potent compound was 3,4-dihydrobenz[a]anthracen-1(2 H)-one (EC 20 : 0.4 µM). Other active compounds in order of AhR agonist activity were the following: 1,4-chrysenequinone > 1,2-benzanthraquinone > benzanthrone ≈ 11H-benzo[a]fluoren-11-one > 11H-benzo[b]fluorene-11-one. In this study, PAH derivatives having 2-4 aromatic rings were tested. Especially PAH quinones with four rings and PAH ketones with three or four rings had AhR agonist activity [ Fig. 2(a), (c) ], which raises the possibility of a structure-activity relationship. This relationship was observed in the estrogenic and antiestrogenic activities of hydroxylated PAHs with two to six rings through ER binding. 15) The author is now studying on the AhR agonistic and antagonistic activity of PAH quinones and ketones with five rings or more to classify the structure activity relationship.
TR-CALUX Assay
TR agonistic/antagonistic effects were not observed for the tested compounds in the concentration range of this study. However, interestingly, 7 PAH derivatives showed potentiating activity (Fig. 4) . These potentiating activities appeared at concentrations over 1 µM (in well). 11H-Benzo[a]fluoren-11-one elicited the highest poten- tiating activity. The relative to the activity of T3 at 25 µM is over 200% [Fig. 4(a) ]. Table 2 
TTR-Binding Assay
DISCUSSION
The PAH derivatives examined in this study were polar compounds (i.e., ketones and quinones) compared with their parental PAHs and possess A hyphen denotes a lack of TTR-binding activity. All measurements were conducted in duplicate, and all experiments were performed once or twice. The concentration of test compound was 25 µM.
weaker binding activity for AhR than PAHs do. Because the binding activities of PAH ketones and quinones were stronger than those of hydroxylated PAHs. 16) It has been reported that oxygenated PAHs which are polar compounds contribute more greatly than PAHs to the AhR activity of environmental air samples. 17, 18) PAH ketones and quinones originating from gasoline and diesel engine exhausts are present at comparatively high concentrations (e.g., 11H-benzo[a]fluoren-11-one: 1.026 ± 0.037 ng/m 3 , 5) comparing with other detected compounds, and 9,10-PQ also exist at high concentration in ambient air. 6) The high concentration of PAH ketones and quinones in the atmosphere suggest that large amount of human exposure to these compounds through respiration.
Although the AhR binding activity of hydroxylated PAHs were lower than those of PAH quinones and ketones, hydroxylated PAHs are in cigarette smoke 19) and act as endocrine disruptors (i.e., having estrogen-like activity). Several PAH hydroxides were shown to have estrogenic/antiestrogenic activity in a reporter gene assay. 20, 21) Additionally, air samples reportedly possess toxicity such as mutagenicity, carcinogenicity and reactive oxygen species. 22, 23) As a possible contributor to these activities, PAHs and/or PAH derivatives such as ketones and quinines are considered. The phenomenon of 1,4-Chrisenequinone's bell-shaped activity was similar to that of endocrine-disrupter chemicals (Fig. 3) . This mechanism is unknown, but further studies are needed.
PAH derivatives did not show any significant TR β agonist or antagonist activity. Therefore, it is presumed that PAH derivatives do not bind di- rectly to TR. However, some of these compounds showed potentiation effects via TR, suggesting a possibility that they interact with TR agonists (e.g., T3) or cofactors related to TR-mediated gene expressions. For revealing these mechanisms, an important finding was CYP1A production by the interaction of coexisting compounds, 24) although this has not yet been reported in the case of TR. The CYP1A is usually induced by the production of AhR and increasing binding activity of AhR-Arnt and Xenobiotics Responsive Elements (XRE). 25) Differently from this AhR relating reaction, phorbol-12-myristate-13-acetate (PMA) is not an AhR agonist (therefore, it does not cause XREbinding of AhR-Arnt), but it does enhance CYP1A1 expression in human hepatocellular carcinoma cells (HepG2)-derived cells. 26, 27) This phenomenon also involves AhR-related modulation via another signaling pathway and is unrelated to the increase of AhR expression or the XRE-binding activity of AhR-Arnt. Such findings underscore the necessity of determining how TR potentiation is affected by PAHs and/or PAH derivatives.
Thyroid hormones are necessary for many physiological activities. They are especially important in early brain development requires thyroid hormones, 28, 29) where they control neuronal and glial proliferation in definitive brain regions and regulate neuronal migration and differentiation. 30) Several polyhalogenated aromatic compounds bind to TTR, possibly resulting in the decrease of thyroid hormone level and negative effects on fetal brain development. Among those compounds, certain PCBs and their hydroxylated and methylsulfonate metabolites structurally resemble thyroid hormones and actually possess TTR-binding activities. 31) Especially, ortho-substituted PCB congeners are more neuroactive than the non-ortho-substituted congeners. 32) Metabolites of PCBs such as hydroxylated polychlorinated biphenyls (OH-PCBs) bind strongly to TTR. The in vivo effects of OH-PCBs on thyroidal mode of action through TTR might be explained by the following three hypotheses. First, TTR might work for selective retention of these compounds in plasma. Secondly, TTR might facilitate transport of the PCB metabolites over the placenta to the fetal compartment. Thirdly, TTR decreases maternal and fetal plasma T4 levels by competition with the natural ligand T4. 10) In fact, OH-PCBs have low affinities for human TR in vitro, 33, 34) although they have a thyroid hormonelike affinity for serum TTR. Consequently, OHPCBs have actual effects through binding to TTR rather than binding to TR. In this report, many PAH derivatives have binding activity to TTR. PAH quinones (1,4-NQ, 1,4-AQ, 1,4-CQ and B[c]P-1,4-Q) have stronger activity than hydroxylated PAHs (Table 2 ). It is interesting that, from the viewpoint of structural features, the active compounds are para-quinone PAHs without 1,2-BAQ. Apparently, a similarity in structures exists between two active compounds: para-quinone PAHs and para-hydroxylated PCBs. These mechanisms are unknown still now, and further studies of structural activity relationship and investigations of more detail toxicity are needed. PAH derivatives have no halogen groups, which is a key to their persistence in vivo. Residual concentrations and persistency of PAH derivatives in vivo are also of concern when considering their risk in terms of endocrine disruption.
